STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4150 by analyst upside · 2026-06-27
OSCR
Oscar Health, Inc.
Healthcare · Market Cap $9B · P/E 0x
ANALYST PRICE TARGET
-24.1%
implied upside to consensus target
Current Price $29.79
Consensus Target $22.6
Bull Target $35.0
Bear Target $13.0
Analysts Covering 10
ANALYST CONSENSUS — HOLD
Strong Buy
2
Buy
0
Hold
5
Sell
3
52-Week Low $10.69
52-Week High $30.38
YTD Return +99.0%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) N/A
Forward P/E 20.1x
EPS (TTM) $-0.54
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $13.3B
Profit Margin -0.3%
52-WEEK RANGE
52-Week Low $10.69
52-Week High $30.38
Current Price $29.79
Bear Target $13.0
Bull Target $35.0
● Now $29.79 ● Target $22.6
TRADING DATA
Avg Volume 7.4M
YTD Return +99.0%
Analyst Count 10
Consensus Hold
Upside to Target -24.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Oscar Health, Inc. (OSCR) is currently trading at $29.79 with a Wall Street consensus price target of $22.6, which is 24.1% below the current price over the next 12 months. 10 analysts currently cover OSCR, with a consensus rating of Hold — 20% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $35.0, while the most cautious has a target of $13.0.

OSCR operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 99.0% year-to-date and is currently trading near the upper end of its 52-week range of $10.69 – $30.38.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for OSCR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ↑ Upgrade
Equal-Weight → Overweight 2026-06-10 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-05-26 Building track record
UBS — Reiterated
Neutral → Neutral 2026-05-07 33% win rate (6 calls)
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-05-07 Building track record
Baird — Reiterated
Neutral → Neutral 2026-05-07 Building track record
Wolfe Research ● Initiated
Peer Perform 2026-05-06 Building track record
Jefferies ↑ Upgrade
Underperform → Hold 2026-04-20 50% win rate (6 calls)
UBS ↑ Upgrade
Sell → Neutral 2026-01-09 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
35
out of 100
Coverage depth
18/30
Consensus clarity
15/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →